Talk:ChinaPeptides / Archive 1
Archived discussion·1 closed thread
Custom synthesis needs its own risk paragraphResolved
The article treats custom synthesis and stock distribution as two rows in a table. They carry different risks: custom work can produce a technically clean synthesis of the wrong sequence, which no purity figure detects. That deserves prose. — CDMO_Caradoc (talk) 10:11, 5 March 2025 (UTC)
Strongly agree, and it explains why mass confirmation matters more on a custom certificate than on a stock one. The two facts belong in the same paragraph. — MassSpecMarv (talk) 14:29, 5 March 2025 (UTC)
Support. Worth adding that a stock item carries the mislabelling risk instead, so the reader does not read "custom is riskier" out of it. Different risk, not more risk. — PrepHPLC_Pia (talk) 09:05, 6 March 2025 (UTC)
Written, with Pia's symmetry point, and the request to make on a custom order is now in §Ordering and availability. ✓ Resolved — CDMO_Caradoc (talk) 11:52, 7 March 2025 (UTC)